Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.

Johnson KR, Liauw W, Lassere MN.

Ann Oncol. 2014 Jul 23. pii: mdu267. [Epub ahead of print] Review.

PMID:
25057168
[PubMed - as supplied by publisher]
3.

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Halabi S, Rini B, Escudier B, Stadler WM, Small EJ.

Cancer. 2014 Jan 1;120(1):52-60. doi: 10.1002/cncr.28221. Epub 2013 Oct 8.

PMID:
24347384
[PubMed - indexed for MEDLINE]
4.

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.

Delea TE, Khuu A, Heng DY, Haas T, Soulières D.

Br J Cancer. 2012 Sep 25;107(7):1059-68. doi: 10.1038/bjc.2012.367. Epub 2012 Aug 30.

PMID:
22935581
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.

Beauchemin C, Cooper D, Lapierre MÈ, Yelle L, Lachaine J.

Onco Targets Ther. 2014 Jun 18;7:1101-10. doi: 10.2147/OTT.S63302. eCollection 2014.

PMID:
24971020
[PubMed]
Free PMC Article
6.

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Wilkerson J, Fojo T.

Cancer J. 2009 Sep-Oct;15(5):379-85. doi: 10.1097/PPO.0b013e3181bef8cd. Review.

PMID:
19826357
[PubMed - indexed for MEDLINE]
7.

Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, Heinemann V.

Clin Cancer Res. 2013 Jan 1;19(1):225-35. doi: 10.1158/1078-0432.CCR-12-1515. Epub 2012 Nov 13.

PMID:
23149819
[PubMed - indexed for MEDLINE]
Free Article
8.

Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.

Sidhu R, Rong A, Dahlberg S.

Clin Cancer Res. 2013 Mar 1;19(5):969-76. doi: 10.1158/1078-0432.CCR-12-2502. Epub 2013 Jan 9.

PMID:
23303214
[PubMed - indexed for MEDLINE]
Free Article
9.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ.

Eur J Cancer. 2014 Jul;50(10):1766-71. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23.

PMID:
24768571
[PubMed - indexed for MEDLINE]
Free Article
10.

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ.

Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.

PMID:
20960500
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.

Petrelli F, Barni S.

Ann Oncol. 2013 Jan;24(1):186-92. doi: 10.1093/annonc/mds289. Epub 2012 Aug 16.

PMID:
22898038
[PubMed - indexed for MEDLINE]
Free Article
12.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
[PubMed - indexed for MEDLINE]
13.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
14.

Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.

Petrelli F, Barni S.

Med Oncol. 2014 Jan;31(1):776. doi: 10.1007/s12032-013-0776-4. Epub 2013 Nov 23.

PMID:
24271313
[PubMed - indexed for MEDLINE]
15.

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK.

Cancer. 2011 Jun 15;117(12):2637-42. doi: 10.1002/cncr.25750. Epub 2010 Nov 18.

PMID:
21656741
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY.

Br J Cancer. 2014 Apr 15;110(8):1917-22. doi: 10.1038/bjc.2014.25. Epub 2014 Apr 1.

PMID:
24691425
[PubMed - indexed for MEDLINE]
17.

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B.

Eur Urol. 2014 Apr;65(4):713-20. doi: 10.1016/j.eururo.2013.08.010. Epub 2013 Aug 15.

PMID:
23993162
[PubMed - indexed for MEDLINE]
18.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

PMID:
23074403
[PubMed]
Free PMC Article
19.

Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.

Shitara K, Ikeda J, Yokota T, Takahari D, Ura T, Muro K, Matsuo K.

Invest New Drugs. 2012 Jun;30(3):1224-31. doi: 10.1007/s10637-011-9648-y. Epub 2011 Feb 25.

PMID:
21350803
[PubMed - indexed for MEDLINE]
20.

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Tang PA, Bentzen SM, Chen EX, Siu LL.

J Clin Oncol. 2007 Oct 10;25(29):4562-8. Epub 2007 Sep 17. Review.

PMID:
17876010
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk